Eidos Therapeutics is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR.
Eidos Therapeutics Inc.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”EID” api=”yf” style=”font-size: 15px”]
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://eidostx.com
Founded2016
Disease Focus
Development StageClinical
STOCK CODENASDAQ: EID
Address101 Montgomery St, STE 2550, CA 094101San FranciscoUnited States
101 Montgomery St, STE 2550, CA 094101
San Francisco
United States
Contact Number+1 415 887 1471
+1 415 887 1471
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]